MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fmed.2026.1902379

Медицинская библиотека · Frontiers in medicine · 2026

Efficacy, safety, and transcriptomic mechanisms of Fuzheng Yangxin formula for enhanced recovery after coronary artery bypass grafting: a propensity score-matched prospective cohort study.

Yu Jinyang, Wang Yifei, Li Yunhu, Ding Tong, Meng Luyu, Ma Xiaochang, Ling Yunpeng, Gong Yichen

СтатьяПеревод в очереди

Аннотация

BACKGROUND

This study aimed to evaluate the clinical efficacy, safety, and transcriptomic mechanisms of Fuzheng Yangxin Formula (FZYX) for enhanced recovery after coronary artery bypass grafting (CABG) in patients with Qi-Yin deficiency syndrome.

METHODS

This prospective cohort study utilized 1:1 propensity score matching (PSM). Matched patients (n = 144; 72/group) received a 7-day FZYX intervention plus conventional therapy or conventional therapy alone. Assessments included the Seattle Angina Questionnaire Physical Limitation (SAQ-PL) score at 7 days, peak serum creatinine (Cr), B-type natriuretic peptide (BNP), and perioperative complications. Transcriptomic mechanisms were explored via peripheral blood RNA sequencing.

RESULTS

Post-intervention, the FZYX group demonstrated significantly lower peak Cr (68.50 vs. 74.50 μmol/L, unadjusted p = 0.010; adjusted p = 0.0059 via ANCOVA) and peak BNP (751.00 vs. 1231.50 pg/mL, p = 0.019). Although the difference in absolute SAQ-PL scores did not reach statistical significance for superiority (40.00 vs. 35.56, p = 0.055), the FZYX group exhibited a markedly reduced quartile coefficient of dispersion (11.1% vs. 20.0%), indicating a trend towards a more stable physical recovery.

CONCLUSION

FZYX appears to be a safe and promising adjunctive therapy post-CABG. While the primary endpoint was formally negative, exploratory analyses suggest it may provide target organ protection and stable physical recovery, potentially associated with modulating macrophage/monocyte-driven innate inflammation, promoting adaptive immune reconstitution, and accelerating tissue repair.

CLINICAL TRIAL REGISTRATION: Identifier NCT06961136, https://clinicaltrials.gov/study/NCT06961136.

Для цитирования: Yu Jinyang, Wang Yifei, Li Yunhu, Ding Tong, Meng Luyu, Ma Xiaochang, Ling Yunpeng, Gong Yichen. Efficacy, safety, and transcriptomic mechanisms of Fuzheng Yangxin formula for enhanced recovery after coronary artery bypass grafting: a propensity score-matched prospective cohort study.. Frontiers in medicine. 2026. DOI: 10.3389/fmed.2026.1902379.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.